The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
Abstract
PURPOSE: The epidermal growth factor (EGF) receptor is frequently overexpressed in epithelial tumors. C225 is a human-to-murine chimeric monoclonal antibody that binds to the receptor and inhibits growth of cancer cells expressing the receptor. We evaluated the pharmacokinetics and toxicity of C225 in patients with advanced tumors overexpressing EGF receptors. PATIENTS AND METHODS: We treated 52 patients in three successive phase I clinical trials of C225 as a single dose (n = 13), weekly multiple dose (n = 17), and weekly multiple dose with cisplatin (n = 22). C225 dose levels were 5, 20, 50, and 100 mg/m 2. In the study combining C225 with cisplatin, limited to patients with either head and neck or non–small-cell lung cancer, C225 was further escalated to 200 and 400 mg/m 2. Cisplatin was given at a dose of 60 mg/m 2 once every 4 weeks, and treatment was continued for up to 12 weeks if no disease progression occurred. RESULTS: C225 displayed nonlinear pharmacokinetics, with antibody doses in the range of 200 to 400 mg/m 2 being associated with complete saturation of systemic clearance. C225 clearance did not change with repeated administration or with coadministration of cisplatin. Antibodies against C225 were detected in only one patient, and C225-associated toxicity was minimal. Patients experiencing disease stabilization were seen in all studies. In the study combining C225 and cisplatin, nine (69%) of 13 patients treated with antibody doses ≥ 50 mg/m 2 completed 12 weeks of therapy, and two partial responses were observed. CONCLUSION: C225 has dose-dependent pharmacokinetics, and doses that achieve saturation of systemic clearance are well tolerated. C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Autocrine growth factors and cancer
Sporn, M. B., & Roberts, A. B. (1985) · Nature · doi:10.1038/313745a0 · Cited by 1,438
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Self-citationRECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS
Carpenter, G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,281
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Self-citationGoldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Self-citationPetit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Self-citation
Cited by
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Self-citationMonoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Self-citationHidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Self-citationDose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Self-citationComparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Self-citationEpidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M. (2003) · The Journal of Pathology · doi:10.1002/path.1370 · Cited by 590
Segaert, S., & Van Cutsem, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi279 · Cited by 571
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Self-citationEpidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Self-citationIssues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Self-citationCutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Peréz-Soler, R., & Saltz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 486
Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M., & Abbruzzese, J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.040 · Cited by 479
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Self-citationStress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways1
Dent, P., Yacoub, A., Contessa, J., Caron, R., Amorino, G., Valerie, K., Hagan, M. P., Grant, S., & Schmidt-Ullrich, R. (2003) · Radiation Research · doi:10.1667/0033-7587(2003)159[0283:sariao]2.0.co;2 · Cited by 463
Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?
Arteaga, C. L. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2004-31 · Cited by 455
Herbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Epidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
Gold nanoparticles: Emerging paradigm for targeted drug delivery system
Kumar, A., Zhang, X., & Liang, X.-J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.002 · Cited by 371
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100001 · Cited by 336
The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn, J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080003 · Cited by 330
Self-citationReview: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Atkins, D., Reiffen, K.-A., Tegtmeier, C. L., Winther, H., Bonato, M. S., & Störkel, S. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.3a6195.2004 · Cited by 319
Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors
Ritter, C. A., & Arteaga, C. L. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50027 · Cited by 311
Pfister, D. G., Su, Y. B., Kraus, D. H., Wolden, S. L., Lis, E., Aliff, T. B., Zahalsky, A. J., Lake, S., Needle, M. N., Shaha, A. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1792 · Cited by 297
Self-citationSieczkiewicz, G. J., Hussain, M., & Kohn, E. C. (2002) · Ovarian Cancer · doi:10.1007/978-1-4757-3587-1_17 · Cited by 295
(2004) · The Women's Oncology Review · doi:10.3109/14733400410001727592 · Cited by 288
Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg250 · Cited by 277
Vanhoefer, U., Tewes, M., Rojo, F., Dirsch, O., Schleucher, N., Rosen, O., Tillner, J., Kovar, A., Braun, A. H., Trarbach, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.114 · Cited by 261
Self-citationHuang, S.-M., & Harari, P. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006384521198 · Cited by 253
Epidermal growth factor receptor: a promising target in solid tumours
Laskin, J. J., & Sandler, A. B. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.002 · Cited by 253
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1295 · Cited by 159
“For some targeted agents, mechanism-based AEs, such as skin rash can also be used (24).”
BackgroundDeng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Fury, M. G., Lipton, A., Smith, K. M., Winston, C. B., & Pfister, D. G. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0357-5 · Cited by 87
“Cetuximab, a conventional monoclonal antibody directed against EGFR, has an estimated half-life of approximately 7 days [20], suggesting diVerent clearance mechanisms.”
BackgroundSelf-citationPotential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
Gill, K. L., Machavaram, K. K., Rose, R. H., & Chetty, M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0361-4 · Cited by 82
(2001) · PubMed
Metadata
- Authors
- Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., & Mendelsohn, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-14
- Volume
- 18
- Issue
- 4
- Pages
- 904-904
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1939364580
- Cited by
- 741
- References
- 30
- FWCI
- 26.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.